Conference

8th Neuropsychiatric Drug Development Summit

Sep 09, 2025 - Sep 11, 2025

Boston, USA

The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum, capturing advancements across discovery, preclinical, translational, clinical, and regulatory development of innovative neuropsychiatric therapeutics.

Over the 3-day agenda, you’ll join 150+ discovery, preclinical, translational, clinical, and regulatory leaders for deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next-generation neuropsychiatric therapeutics. Additionally, all new for 2025 is the EEG Focus Day, which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development, and the new Investors' Panel, which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape.

Don’t miss out on this unique forum that’s spearheading a new era of more transformative mental health therapeutics.

Plus, Pharma Now readers save an additional 10% on tickets with promo 

code: PNOW10.


About the Organiser

Hanson Wade Limited

Day and Timing

Tuesday, Sep 9 - 11

Location

Boston, USA

Entry Fees

Paid

Frequency

Annually

Event Type

Conference

Duration

3 Days

Website

ter.li

Day and Timing

Tuesday, Sep 9 - 11

Location

Boston, USA

Entry Fees

Paid

Frequency

Annually

Event Type

Conference

Duration

3 Days

Website

ter.li

About the Organiser

Hanson Wade Limited

Ad
Advertisement

More Events

Conference

GCC Regulatory Affairs Pharma Summit

Jun 22, 2026 - Jun 23, 2026

Dubai

Conference

16th Edition SCM Pharma Summit

Jun 19, 2026

Mumbai

Conference

11th Edition NutriThink Conference 2026

Jul 23, 2026 - Jul 24, 2026

Mumbai

View All

News Letter

Subscribe to our Newsletter!

Be the first to get exclusive offers and the latest news